- In March 2025, Illumina Inc. launched its next-generation NovaSeq X Plus sequencing platform in key global markets, offering enhanced throughput, reduced sequencing costs, and integrated AI-powered analytics to accelerate whole genome sequencing applications in clinical and research settings
- In February 2025, the UK government announced a major expansion of its Genomics England program, aiming to sequence an additional 1 million genomes over the next five years to advance rare disease diagnosis, cancer research, and personalized healthcare initiatives
- In January 2025, Thermo Fisher Scientific introduced its Ion Torrent Genexus Dx Integrated Sequencer, a fully automated NGS platform designed for clinical diagnostic use, enabling same-day results and simplifying genomic workflows for oncology and infectious disease applications
- In November 2024, BGI Genomics partnered with the Indian Council of Medical Research (ICMR) to establish a nationwide genomic surveillance program targeting antimicrobial resistance and genetic disorders, marking a significant step toward public health preparedness and precision medicine in India
- In October 2024, CRISPR Therapeutics and Vertex Pharmaceuticals received expanded FDA approval for their gene-editing therapy, Casgevy, for treating additional beta-thalassemia genotypes, reinforcing the role of genomics in advanced therapeutic solutions and personalized treatment approaches
Frequently Asked Questions
Companies such as Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN (Germany), Agilent Technologies (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), PacBio (U.S.), are the major companies in the genomics market.
In March 2025, Illumina Inc. launched its next-generation NovaSeq X Plus sequencing platform in key global markets, offering enhanced throughput, reduced sequencing costs, and integrated AI-powered analytics to accelerate whole genome sequencing applications in clinical and research settings. In January 2025, Thermo Fisher Scientific introduced its Ion Torrent Genexus Dx Integrated Sequencer, a fully automated NGS platform designed for clinical diagnostic use, enabling same-day results and simplifying genomic workflows for oncology and infectious disease applications
The countries covered in the genomics market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
